Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $72,591 | 8 | 85.8% |
| Unspecified | $10,313 | 4 | 12.2% |
| Travel and Lodging | $1,372 | 3 | 1.6% |
| Food and Beverage | $372.62 | 2 | 0.4% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI US SERVICES INC. | $69,491 | 7 | $0 (2024) |
| PRINCIPIA BIOPHARMA INC. | $10,313 | 4 | $0 (2021) |
| Genentech USA, Inc. | $4,845 | 6 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,466 | 1 | SANOFI US SERVICES INC. ($13,466) |
| 2023 | $7,162 | 1 | SANOFI US SERVICES INC. ($7,162) |
| 2022 | $48,863 | 5 | SANOFI US SERVICES INC. ($48,863) |
| 2021 | $6,463 | 3 | PRINCIPIA BIOPHARMA INC. ($6,463) |
| 2020 | $3,850 | 1 | PRINCIPIA BIOPHARMA INC. ($3,850) |
| 2017 | $4,845 | 6 | Genentech USA, Inc. ($4,845) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/12/2024 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $13,465.50 | General |
| 11/14/2023 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $7,162.00 | General |
| 11/19/2022 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $16,187.00 | General |
| 11/14/2022 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $10,744.00 | General |
| 09/19/2022 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $9,432.00 | General |
| 09/12/2022 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $7,550.00 | General |
| 09/12/2022 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $4,950.00 | General |
| 05/24/2021 | PRINCIPIA BIOPHARMA INC. | — | — | Cash or cash equivalent | $1,925.00 | Research |
| Study: An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patients With IgG4-Related Disease | ||||||
| 03/29/2021 | PRINCIPIA BIOPHARMA INC. | — | — | Cash or cash equivalent | $1,788.00 | Research |
| Study: An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patients With IgG4-Related Disease | ||||||
| 01/27/2021 | PRINCIPIA BIOPHARMA INC. | — | — | Cash or cash equivalent | $2,750.00 | Research |
| Study: An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patients With IgG4-Related Disease | ||||||
| 12/23/2020 | PRINCIPIA BIOPHARMA INC. | — | — | Cash or cash equivalent | $3,850.00 | Research |
| Study: Dose Find - "An Adaptive" - ITP - po | ||||||
| 10/20/2017 | Genentech USA, Inc. | Actemra (Biological) | Food and Beverage | In-kind items and services | $346.85 | General |
| Category: Immunology | ||||||
| 10/19/2017 | Genentech USA, Inc. | Actemra (Biological) | Consulting Fee | Cash or cash equivalent | $3,100.00 | General |
| Category: Immunology | ||||||
| 10/19/2017 | Genentech USA, Inc. | Actemra (Biological) | Travel and Lodging | In-kind items and services | $681.66 | General |
| Category: Immunology | ||||||
| 10/19/2017 | Genentech USA, Inc. | Actemra (Biological) | Travel and Lodging | In-kind items and services | $564.63 | General |
| Category: Immunology | ||||||
| 10/19/2017 | Genentech USA, Inc. | Actemra (Biological) | Travel and Lodging | Cash or cash equivalent | $126.00 | General |
| Category: Immunology | ||||||
| 10/19/2017 | Genentech USA, Inc. | Actemra (Biological) | Food and Beverage | Cash or cash equivalent | $25.77 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patients With IgG4-Related Disease | PRINCIPIA BIOPHARMA INC. | $6,463 | 3 |
| Dose Find - "An Adaptive" - ITP - po | PRINCIPIA BIOPHARMA INC. | $3,850 | 1 |
About Dr. Gary Hoffman, M.D
Dr. Gary Hoffman, M.D is a Rheumatology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730143173.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Hoffman, M.D has received a total of $84,648 in payments from pharmaceutical and medical device companies, with $13,466 received in 2024. These payments were reported across 17 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($72,591).
Practice Information
- Specialty Rheumatology
- Location Cleveland, OH
- Active Since 04/13/2006
- Last Updated 02/07/2008
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1730143173
Products in Payments
- Actemra (Biological) $4,845
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Cleveland
Leonard Calabrese, Do, DO
Rheumatology — Payments: $2.1M
Muhammad Khan, Md, MD
Rheumatology — Payments: $676,848
Kristin Highland, M.d, M.D
Rheumatology — Payments: $630,614
Chad Deal, Md, MD
Rheumatology — Payments: $525,018
M Elaine Husni, M.d, M.D
Rheumatology — Payments: $301,718
Brian Mandell, M.d, M.D
Rheumatology — Payments: $185,593